GC
IRD

Guggenheim Capital’s Opus Genetics IRD Stock Holding History

Guggenheim Capital’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-172
Closed -$42K – 2878
2017
Q1 		$42K Buy
172
+29
+20% +$3.76K ﹤0.01% 2741
2016
Q4 		$10K Hold
143
– – ﹤0.01% 2879
2016
Q3 		$14K Sell
143
-1
-0.7% -$121 ﹤0.01% 2852
2016
Q2 		$17K Hold
144
– – ﹤0.01% 2819
2016
Q1 		$23K Buy
144
+78
+118% +$13K ﹤0.01% 2821
2015
Q4 		$12K Hold
66
– – ﹤0.01% 2940
2015
Q3 		$17K Buy
66
+8
+14% +$2.17K ﹤0.01% 2907
2015
Q2 		$17K Hold
58
– – ﹤0.01% 3004
2015
Q1 		$20K Hold
58
– – ﹤0.01% 2994
2014
Q4 		$19K Buy
58
+17
+41% +$5.87K ﹤0.01% 2968
2014
Q3 		$16K Sell
41
-97
-70% -$34.9K ﹤0.01% 2971
2014
Q2 		$58K Sell
138
-14
-9% -$6.36K ﹤0.01% 3064
2014
Q1 		$79K Buy
152
+65
+75% +$35.2K ﹤0.01% 3062
2013
Q4 		$21K Buy
87
+5
+6% +$1.06K ﹤0.01% 3130
2013
Q3 		$18K Hold
82
– – ﹤0.01% 3022
2013
Q2 		$17K Buy
+82
New +$14.1K ﹤0.01% 2996

Other funds holding IRD

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
HVIA
Hudson Valley Investment Advisors Goshen, New York $823M AUM 31.4% 1-Year Est. Return
NFC
Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Guggenheim Capital's IRD Position: Q2 2017 in Review

Guggenheim Capital sold out of Opus Genetics (IRD) in Q2 2017, closing a stake of 172 shares — an estimated $42K sold.

Guggenheim Capital first reported a position in IRD in Q2 2013 and held it in 16 quarters. The position peaked at $79K in Q1 2014. 23 funds tracked by Wall St. Rank hold IRD as of Q2 2017.

  • Guggenheim Capital reported no remaining Opus Genetics position as of Q2 2017 after selling out during the quarter.
  • Guggenheim Capital sold 172 Opus Genetics shares in Q2 2017, an estimated $42K.
  • Guggenheim Capital first reported a position in Opus Genetics in Q2 2013 and held it in 16 quarters.
  • Guggenheim Capital's Opus Genetics position peaked at $79K in Q1 2014.
  • 23 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2017.

Based on Guggenheim Capital's 13F filing for Q2 2017, filed 14 Aug 2017.